SOUTH SAN FRANCISCO, Calif., Jan. 27, 2020 -- Catalyst Biosciences, Inc. (NASDAQ: CBIO), today announced one oral and three poster presentations at the 13th Annual Congress of.

Catalyst Biosciences, Inc. (CBIO), a clinical-stage biopharmaceutical company developing novel treatments for hemophilia and other rare bleeding disorders, (the Company), today announced the closing of an underwritten public offering of 5,307,692 shares of its common stock, offered at a price of $6.50 per share to the public, which includes the exercise in full by the underwriters of their 30-day option to purchase up to an additional 692,307 shares of its common stock. The gross proceeds to the Company from this offering were approximately $34.5 million, before deducting underwriting discounts and commissions and other estimated offering expenses payable by the Company.

Catalyst Biosciences, Inc. (CBIO), today announced positive efficacy and safety data from its Phase 2b trial of DalcA, a next-generation subcutaneously (SQ) administered Factor IX (FIX) therapy being developed for the treatment of hemophilia B. The data were presented by Johnny Mahlangu, M.B.B.Ch., M.Med, F.C.Path, professor of haematology, faculty of health sciences, head of the School of Pathology at the University of Witwatersrand in Johannesburg, South Africa, and principal investigator in the clinical trial in an oral presentation at the 13th Annual Congress of the European Association for Haemophilia and Allied Disorders (EAHAD) in The Hague, Netherlands. Data from the trial showed that 28 days of daily SQ dosing of DalcA achieved protective target FIX levels of >12%, with steady state FIX levels of up to 27% after 14 days with no bleeds, demonstrating effective prophylaxis and the potential for lower or less frequent dosing.

Catalyst Biosciences, Inc. (CBIO), a clinical-stage biopharmaceutical company developing novel treatments for hemophilia and other rare bleeding disorders,  (the Company), today announced the pricing of an underwritten public offering of 4,615,385 shares of its common stock, offered at a price of $6.50 per share to the public. Additionally, the Company has granted the underwriters a 30-day option to purchase up to an additional 692,307 shares of its common stock. All of the shares in the offering are being offered by the Company.

Catalyst Biosciences, Inc. (CBIO), a clinical-stage biopharmaceutical company developing novel treatments for hemophilia and other rare bleeding disorders (the Company), today announced that it is offering shares of its common stock in an underwritten public offering. The offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering. In addition, the Company expects to grant the underwriters of the offering a 30-day option to purchase up to an additional 15% of the number of shares of common stock offered in the public offering.

Catalyst Biosciences, Inc. (CBIO), a clinical-stage biopharmaceutical company developing novel treatments for hemophilia and other rare bleeding disorders, today announced the appointment of Geoffrey Shiu Fei Ling, M.D. and Sharon Tetlow to the Company’s Board of Directors, effective January 15, 2020. Ms. Tetlow is Managing Partner and Founder of Potrero Hill Advisors. Throughout her career as a serial Chief Financial Officer, Ms. Tetlow has held board seats, served on Audit and Transaction Committees through successful acquisitions, served as the board’s financial expert and has been the CFO of public companies.

Catalyst Biosciences, Inc. (CBIO), today announced that Nassim Usman, Ph.D., president and chief executive officer of Catalyst Biosciences, will present a corporate overview at the Cowen Healthcare Conference at 8:40 a.m. ET on Tuesday, March 3, 2020, in Boston. Catalyst is a clinical-stage biopharmaceutical company focused on addressing unmet needs in rare diseases and systemic complement mediated disorders.

Presented positive clinical and pre-clinical data from its MarzAA and DalcA hemophilia programs Announced a global license and collaboration agreement with Biogen to develop.

Most investors tend to think that hedge funds and other asset managers are worthless, as they cannot beat even simple index fund portfolios. In fact, most people expect hedge funds to compete with and outperform the bull market that we have witnessed in recent years. However, hedge funds are generally partially hedged and aim at […]

Top Ranked Momentum Stocks to Buy for April 21st

Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week highs on Feb. 6) Acceleron Pharma Inc (NASDAQ: XLRN ) Alector Inc (NASDAQ: ...

SOUTH SAN FRANCISCO, Calif., April 28, 2020 -- Catalyst Biosciences, Inc. (NASDAQ: CBIO), a biopharmaceutical company developing novel subcutaneous (SQ) therapies for.

SOUTH SAN FRANCISCO, Calif., April 06, 2020 -- Catalyst Biosciences, Inc. (NASDAQ: CBIO), a biopharmaceutical company that is developing novel subcutaneous (SQ) therapies for.

Nassim Usman became the CEO of Catalyst Biosciences, Inc. (NASDAQ:CBIO) in 2015. This analysis aims first to contrast...

Companies In The News Are: CAG, CBIO, MLHR, DRI

Benzinga Pro's Stocks To Watch For Thursday NIKE (NKE) - Shares were up 0.4% premarket ahead of earnings from the company after hours Thursday. Analysts expect NIKE to report around $0.58 in quarterly ...

Catalyst Biosciences has been on a bit of a cold streak lately, but there might be light at the end of the tunnel for this overlooked stock.

“We are pleased to have successfully completed the DalcA Phase 2b trial during this challenging pandemic and remain on track to report final results later this quarter,” said Nassim Usman, Ph.D., president and chief executive officer of Catalyst. ”Interim trial data presented at European Association for Haemophilia and Allied Disorders (EAHAD) 2020 earlier this year clearly demonstrated the potential for DalcA to significantly change the treatment paradigm in hemophilia B; we look forward to continuing its development.”

It is a pleasure to report that the Catalyst Biosciences, Inc. (NASDAQ:CBIO) is up 38% in the last quarter. But that...

MarzAA Phase 3 study first patient enrollment targeted before year end following FDA and EMA regulatory feedback DalcA Phase 2b study completed, final data to be presented in.